Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Farmers Insurance
McKesson
Cerilliant
UBS
Federal Trade Commission
Daiichi Sankyo
Argus Health
Citi

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021945

« Back to Dashboard

NDA 021945 describes MAKENA (AUTOINJECTOR), which is a drug marketed by Amag Pharma Usa and is included in one NDA. It is available from one supplier. There are eight patents protecting this drug. Additional details are available on the MAKENA (AUTOINJECTOR) profile page.

The generic ingredient in MAKENA (AUTOINJECTOR) is hydroxyprogesterone caproate. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the hydroxyprogesterone caproate profile page.
Summary for 021945
Tradename:MAKENA (AUTOINJECTOR)
Applicant:Amag Pharma Usa
Ingredient:hydroxyprogesterone caproate
Patents:8
Formulation / Manufacturing:see details
Pharmacology for NDA: 021945
Ingredient-typeProgesterone Congeners
Suppliers and Packaging for NDA: 021945
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MAKENA hydroxyprogesterone caproate SOLUTION;INTRAMUSCULAR 021945 NDA AMAG Pharmaceuticals, Inc. 64011-243 N 64011-243-01
MAKENA PRESERVATIVE FREE hydroxyprogesterone caproate SOLUTION;INTRAMUSCULAR 021945 NDA AMAG Pharmaceuticals, Inc. 64011-243 N 64011-243-01

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAMUSCULARStrength1250MG/5ML (250MG/ML)
Approval Date:Feb 3, 2011TE:RLD:Yes
Regulatory Exclusivity Expiration:Feb 3, 2018
Regulatory Exclusivity Use:TO REDUCE THE RISK OF PRETERM BIRTH IN WOMEN WITH SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAMUSCULARStrength250MG/ML (250MG/ML)
Approval Date:Feb 19, 2016TE:RLD:Yes
Regulatory Exclusivity Expiration:Feb 3, 2018
Regulatory Exclusivity Use:TO REDUCE THE RISK OF PRETERM BIRTH IN WOMEN WITH SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH

Profile for product number 004

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;SUBCUTANEOUSStrength275MG/1.1ML (250MG/ML)
Approval Date:Feb 14, 2018TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Oct 4, 2026Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
AstraZeneca
Farmers Insurance
Colorcon
US Department of Justice
Citi
Cantor Fitzgerald
Express Scripts
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.